Jacobio’s SHP2 Inhibitor Sitneprotafib Gains Recognition in Cancer Research

Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) has issued an update.

Jacobio Pharmaceuticals has announced that its SHP2 inhibitor, sitneprotafib (JAB-3312), has been featured in the journal Clinical Cancer Research, highlighting its potential in combination therapies for cancer treatment. The study shows that sitneprotafib enhances the efficacy of other cancer drugs, such as KRAS G12C inhibitor glecirasib, and improves outcomes in resistant cancer models. This development positions Jacobio as a key player in the oncology drug market, with sitneprotafib being the first SHP2 inhibitor to reach phase III clinical trials globally.

More about Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd. is a pharmaceutical company focused on developing innovative products and solutions to improve patient health. The company specializes in novel molecular targets across six major signaling pathways, including KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC. Jacobio aims to be a global leader in drug research and development, with R&D centers in Beijing, Shanghai, and Boston.

Average Trading Volume: 8,331,700

Technical Sentiment Signal: Buy

Current Market Cap: HK$3.06B

See more insights into 1167 stock on TipRanks’ Stock Analysis page.